GLTO Logo

Galecto, Inc. (GLTO) 

NASDAQ
Market Cap
$9.6M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
550 of 776
Rank in Industry
295 of 433

Largest Insider Buys in Sector

GLTO Stock Price History Chart

GLTO Stock Performance

About Galecto, Inc.

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 …

Insider Activity of Galecto, Inc.

Over the last 12 months, insiders at Galecto, Inc. have bought $0 and sold $0 worth of Galecto, Inc. stock.

On average, over the past 5 years, insiders at Galecto, Inc. have bought $14.71M and sold $2.42M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 5,000 shares for transaction amount of $10,750 was made by Schambye Hans T. (Chief Executive Officer) on 2022‑03‑22.

List of Insider Buy and Sell Transactions, Galecto, Inc.

2023-08-15Sale10 percent owner
822,680
3.5684%
$0.75$617,010-7.48%
2023-07-31Sale10 percent owner
209,400
0.8023%
$3.00$628,200-79.55%
2023-07-25Sale10 percent owner
39,200
0.1462%
$2.92$114,464-79.34%
2023-07-13Sale10 percent owner
194,700
0.7339%
$2.40$467,280-74.19%
2023-04-17Sale10 percent owner
12,429
0.0461%
$1.97$24,485-66.21%
2023-04-17Sale10 percent owner
13,089
0.0485%
$1.97$25,785-66.21%
2023-04-14Sale10 percent owner
39,355
0.1501%
$1.86$73,200-63.13%
2023-04-14Sale10 percent owner
41,446
0.158%
$1.86$77,090-63.13%
2023-04-13Sale10 percent owner
13,243
0.0519%
$1.82$24,102-61.26%
2023-04-13Sale10 percent owner
13,946
0.0546%
$1.82$25,382-61.26%
2023-04-12Sale10 percent owner
2,363
0.0093%
$1.81$4,277-60.83%
2023-04-11Sale10 percent owner
13,946
0.0543%
$1.82$25,382-61.41%
2023-04-10Sale10 percent owner
51,228
0.1984%
$1.79$91,698-60.81%
2023-04-06Sale10 percent owner
9,665
0.0396%
$2.00$19,330-62.87%
2023-04-05Sale10 percent owner
92,965
0.3672%
$2.18$202,664-67.11%
2022-03-22PurchaseChief Executive Officer
5,000
0.0194%
$2.15$10,750-12.79%
2022-03-22PurchaseChief Medical Officer
14,604
0.057%
$2.16$31,545-12.79%
2021-12-03PurchaseChief Financial Officer
4,000
0.0164%
$2.49$9,960-16.67%
2021-12-03PurchaseGeneral Counsel
2,000
0.0082%
$2.48$4,960-16.67%
2021-11-09PurchaseChief Executive Officer
4,500
0.0178%
$3.50$15,750-40.86%

Insider Historical Profitability

<0.0001%
Khuong Chau Quang
2579657
195.8755%
$7.2910
Novo Holdings A/S10 percent owner
2497791
189.6593%
$7.2910
Christgau Stephandirector
546136
41.4686%
$7.2910
ORBIMED ADVISORS LLC10 percent owner
97204
7.3808%
$7.29115
Schambye Hans T.Chief Executive Officer
52428
3.9809%
$7.2930<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Novo Holdings A/S$1.95M9.212.5M0%+$00.14
Renaissance Technologies$452,000.002.13578,983+42.27%+$134,288.54<0.01
The Vanguard Group$172,536.000.82221,2000%+$0<0.0001
Geode Capital Management$162,535.000.77208,3330%+$0<0.0001
Citadel Advisors LLC$72,931.000.3593,501+29.09%+$16,433.09<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.